Trade Mark Journal No.2026/013 27 March 2026

UK00004355348 16 March 2026 (5)

BEMLEYO

International priority date claimed: 26 January 2026 (United States of America) (99617683)

Class 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer’s disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, osteoarthritis, pain, Parkinson’s disease, peripheral arterial disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases.

Eli Lilly and Company

Representative: Page, White & Farrer Limited